Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 55, Issue 5, Pages 541-557
Publisher
Wiley
Online
2021-12-09
DOI
10.1111/apt.16723
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative Analysis of 3-Year Persistence With Vedolizumab Compared With Antibodies Against Tumor Necrosis Factor-Alpha in Patients With Inflammatory Bowel Disease in Germany
- (2020) Ulf Helwig et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- P524 Administration and monitoring of biologic therapy in patients with inflammatory bowel disease: A national Danish survey
- (2020) S Volmar et al. Journal of Crohns & Colitis
- OP35 Treatment outcomes of inflammatory bowel disease in the biological era—a nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study
- (2020) M Zhao et al. Journal of Crohns & Colitis
- Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study
- (2020) Johan Burisch et al. Lancet Gastroenterology & Hepatology
- Validation of ulcerative colitis and Crohn’s disease and their phenotypes in the Danish National Patient Registry using a population-based cohort
- (2020) Bobby Lo et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Earlier Anti-Tumor Necrosis Factor Therapy of Crohn’s Disease Correlates with Slower Progression of Bowel Damage
- (2019) Hinaben Panchal et al. DIGESTIVE DISEASES AND SCIENCES
- Long‐term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first‐line biologics
- (2019) Toshihiro Inokuchi et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy
- (2019) Chao Chen et al. INFLAMMATORY BOWEL DISEASES
- Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
- (2019) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNFα Therapy for Inflammatory Bowel Disease
- (2019) Eun Jin Jang et al. CLINICAL DRUG INVESTIGATION
- Impact of Genes and the Environment on the Pathogenesis and Disease Course of Inflammatory Bowel Disease
- (2019) Mirabella Zhao et al. DIGESTIVE DISEASES AND SCIENCES
- Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow Up in a Danish Population-Based Inception Cohort
- (2019) Bobby Lo et al. Journal of Crohns & Colitis
- Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience
- (2019) Jean Lawton et al. United European Gastroenterology Journal
- Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study
- (2019) Sanjay K Murthy et al. GUT
- Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
- (2019) Nicholas A Kennedy et al. Lancet Gastroenterology & Hepatology
- Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era—Results from the Dutch Population-Based IBDSL Cohort
- (2018) Steven F G Jeuring et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study
- (2018) Johan Burisch et al. GUT
- Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses—Part II
- (2018) Simon R Knowles et al. INFLAMMATORY BOWEL DISEASES
- Upfront Combination Therapy, Compared with Monotherapy, for Patients Not Previously Treated with a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study
- (2018) Laura E. Targownik et al. Clinical Gastroenterology and Hepatology
- Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort—An Epi-IBD Study
- (2018) Johan Burisch et al. Journal of Crohns & Colitis
- Treatment Persistence for Infliximab Versus Adalimumab in Crohnʼs Disease
- (2017) Pablo Olivera et al. INFLAMMATORY BOWEL DISEASES
- The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease
- (2016) N. Narula et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease
- (2016) J. Cosnes et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients
- (2016) L. Angelison et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
- (2016) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Improvements in the Long-Term Outcome of Crohn’s Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort
- (2016) Steven F G Jeuring et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Anti-TNF Therapy Within 2 Years of Crohnʼs Disease Diagnosis Improves Patient Outcomes
- (2016) Christopher Ma et al. INFLAMMATORY BOWEL DISEASES
- Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease
- (2015) E. Safroneeva et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONICpost hocanalysis
- (2015) J.-F. Colombel et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
- (2015) Veerle Nuij et al. Journal of Crohns & Colitis
- Bowel Damage as Assessed by the Lémann Index is Reversible on Anti-TNF Therapy for Crohn’s Disease
- (2015) Gionata Fiorino et al. Journal of Crohns & Colitis
- The Danish National Patient Registry: a review of content, data quality, and research potential
- (2015) Morten Schmidt et al. Clinical Epidemiology
- The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009
- (2014) V. Chhaya et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Impact of Timing and Duration of Thiopurine Treatment on First Intestinal Resection in Crohn's Disease: National UK Population-Based Study 1989–2010
- (2014) Sukhdev Chatu et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Disease Course and Surgery Rates in Inflammatory Bowel Disease: A Population-Based, 7-Year Follow-Up Study in the Era of Immunomodulating Therapy
- (2014) Marianne K Vester-Andersen et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–2011
- (2013) Christine Rungoe et al. GUT
- Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study
- (2012) Mirthe Emilie van der Valk et al. GUT
- Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study
- (2012) Marte Lie Høivik et al. GUT
- Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD
- (2012) Pauliina Molander et al. Journal of Crohns & Colitis
- Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn’s disease
- (2011) M. A. Kamm et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Epidemiology and Natural History of Inflammatory Bowel Diseases
- (2011) Jacques Cosnes et al. GASTROENTEROLOGY
- Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
- (2010) Matthieu Allez et al. Journal of Crohns & Colitis
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
- (2008) Geert D'Haens et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now